Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196930 | 1.00 | MAPT (0.74) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL8485074 | 0.85 | MAPT (1.00) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL8485080 | 0.85 | MAPT (1.00) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL22009555 | 0.84 | TSHR (0.60) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25185071 | 0.84 | MAPT (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25193659 | 0.84 | MAPT (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25196901 | 0.84 | MAPT (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL8484340 | 0.84 | MAPT (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25232280 | 0.84 | MAPT (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL8484337 | 0.84 | MAPT (0.76) | MAPTMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167058-B1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIV LOUISVILLE RES FOUND (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2167058-B1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIV LOUISVILLE RES FOUND (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| WO-2013007766-A1 | MEANS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS | VIB VZW (BE) | 2013-01-17 | — | — | WO | disclosed |
| WO-2012119949-A1 | MEANS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VIB VZW (BE) | 2012-09-13 | — | — | WO | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8088385-B2 | PFKB3 inhibitor for the treatment of a proliferative cancer | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088385-B2 | PFKB3 inhibitor for the treatment of a proliferative cancer | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088385-B2 | PFKB3 inhibitor for the treatment of a proliferative cancer | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2008156783-A2 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | MAPT 3600/4885MEN1 1940/4885KMT2A 2305/4885 |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | MAPT 3600/4885MEN1 1940/4885KMT2A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.